Back to search

Article

Impact of Smoking on Immune Checkpoint Inhibitor Treatment Outcomes in Patients with Non-Squamous Non-Small Cell Lung Cancer with High PD-L1 Expression: A Real-World Observational Study

2024-03-29

Abstract excerpt

<title>Abstract</title> <p>Background Smoking history is increasingly recognized as a potential prognostic indicator for immune checkpoint inhibitor (ICI) efficacy in metastatic non-small-cell lung cancer (NSCLC). However, the findings of most studies have not reached statistical significance. Furthermore, no studies have evaluated the impact of smoking specifically on non-squamous cell NSCLC with high programme...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
498266e5-c214-50fc-a76f-27e08f155515
DOI
10.21203/rs.3.rs-4154113/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Impact of Smoking on Immune Checkpoint Inhibitor Treatment Outcomes in Patients with Non-Squamous Non-Small Cell Lung Cancer with High PD-L1 Expression: A Real-World Observational StudyDOI 10.21203/rs.3.rs-4154113/v1
Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.Semantic proximity
PD-L1 expression in patients with non-small-cell lung cancer is associated with sex and genetic alterations: A retrospective study within the Caucasian population.Semantic proximity
Efficacy and safety of different PD-1 inhibitors as first-line treatment for advanced or metastatic squamous non-small cell lung cancer: A retrospective real-world studySemantic proximity
Maintenance therapy for metastatic non-squamous non-small cell lung cancer: lymphopenia as a biomarker for pemetrexed cessationSemantic proximity
Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival OutcomesSemantic proximity
Non-small cell lung cancer (NSCLC): characteristics, risk factors, molecular profile patterns, and treatment - a retrospective cohort study from Palestine.Semantic proximity
Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant).Semantic proximity
A scoping review on the significance of programmed death-ligand 1-inhibiting microRNAs in non-small cell lung treatment: A single-cell RNA sequencing-based studySemantic proximity
Study on PD-L1 Expression in NSCLC Patients and Related Influencing Factors in the Real World.Semantic proximity
Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco.Semantic proximity
Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients.Semantic proximity
Outcome of non-small-cell lung cancer with driven mutations treated with anti-PD-(L)1 agents: A systematic review.Semantic proximity
Select a neighboring publication to make it the new centre.